Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. Immuno-pharmaceutical company AIM Imm...
Streetwise Reports | March 10, 2020 |

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. Early this morning, clinical-stage biopharmaceutical company Deciphera Pharmaceutic...
Streetwise Reports | August 14, 2019 |

XPhyto: Outperforming Leading Cannabis Stocks

I recently wrote about an increasingly popular but still mostly overlooked medical cannabis company that is innovating industry-leading transdermal and oral thin film drug delivery systems. ( https://stockhouse.com/opinion/independent-reports/2020/01/08/the-golden-bullet-for-d...
Marc Davis | January 29, 2020 |

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector...
Mario Hose | March 4, 2020 |

Trillion-dollar US infrastructure plan will draw in plenty of metal

Donald Trump appears to have torn a page from Ahead of the Herd’s manual for recharging the US economy. In an earlier article we said what the global economy really needs, in this low-growth, spending-stalled environment brought about by the pandemic, is...
Richard (Rick) Mills | June 19, 2020 |

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Co

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary Source: Gail Dutton of The Life Sciences Report (12/22/15) https://www.thelifesciencesreport.com/pub/na/aethlon-medical...
Gail Dutton | December 23, 2015 |

NASDAQ and DOW - Two Spectrum’s of the Stock Market

Our researchers believe the NQ and YM chart illustrates a very different dynamic which is currently at play in the US Stock Markets. The NQ, the Technology heavy NASDAQ futures, appears to have stalled near the 75% Fibonacci price retracement level whereas the YM, the Blue Chi...
Chris Vermeulen | March 4, 2019 |

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. In a March 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Nabriva Therapeutics Plc (NBRV:NASDAQ) has two antibiotics up for approval...
Streetwise Reports | March 21, 2019 |

Bacteria Test Developer Reiterates Revenue Should Double in 2019

The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. In a May 31 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. lowered its target price on T2 BioSystems Inc. (TTOO:NASDAQ) to $10 per sha...
Streetwise Reports | June 10, 2019 |

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. San Diego, Calif.-based biopharmaceutical company ACADIA Pharmaceu...
Streetwise Reports | September 10, 2019 |
1 2 3 4 5 6 7 8 9 10 ...